Revance Therapeutics (RVNC) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Revance Therapeutics (RVNC) Misses Q4 EPS by 1c

Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update

February 24, 2020 4:05 PM EST

- Conference call and webcast today at 4:30 p.m. ET -

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today reported financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.

Key Fourth Quarter 2019 Events and Subsequent Updates

Commercial:

BLA for DAXI in Glabellar Lines Accepted by FDA, PDUFA Date Announced. In... More